目的:探讨CHFR(checkpoint with FHA and ring finger)基因在B细胞非霍奇金淋巴瘤(B-NHL)中的表达水平及其与临床病理特征之间的关系。方法:采用荧光定量PCR方法检测81例B细胞非霍奇金淋巴瘤组织和38例淋巴结反应性增生组织(RH)CHFR mRN...目的:探讨CHFR(checkpoint with FHA and ring finger)基因在B细胞非霍奇金淋巴瘤(B-NHL)中的表达水平及其与临床病理特征之间的关系。方法:采用荧光定量PCR方法检测81例B细胞非霍奇金淋巴瘤组织和38例淋巴结反应性增生组织(RH)CHFR mRNA的表达水平。结果:①81例B-NHL组织中低水平表达CHFR mRNA,其中2例表达缺失;而在淋巴结反应性增生组中该基因全部表达,差异有统计学意义(P<0.05)。②B-NHL患者中I+II期组和III+IV期组CHFR mRNA表达存在差异,III+IV期表达水平低于I+II期,差异有统计学意义(P<0.05);B-NHL组按IPI评分分0-1分组和2-5分组,高评分组CHFR mRNA表达量低于低评分组,差异具有统计学意义(P<0.05);而CHFR mRNA表达量与年龄、性别、有无症状、LDH水平及ECOG评分无相关性。结论:CHFR表达水平的降低在非霍奇金淋巴瘤的发生过程中具有一定作用,并与其恶性程度及进展相关。展开更多
Rituximab has provided a revolutionary contribution to the treatment of B-cell non-Hodgkin’s lymphomas (NHL). A high prevalence of hepatitis C virus (HCV) infection has been described in B-cell NHL patients. Cases of...Rituximab has provided a revolutionary contribution to the treatment of B-cell non-Hodgkin’s lymphomas (NHL). A high prevalence of hepatitis C virus (HCV) infection has been described in B-cell NHL patients. Cases of liver dysfunction in HCV-positive patients have been reported with Rituximab-containing regimens. In this paper we review the recent data regarding the effects of Rituximab in NHL patients with HCV infection. We also added a section devoted to improving communication between oncohaematologists and hepatologists. Furthermore, we propose a common methodological ground to study hepatic toxicity emerging during chemotherapy.展开更多
文摘目的:探讨CHFR(checkpoint with FHA and ring finger)基因在B细胞非霍奇金淋巴瘤(B-NHL)中的表达水平及其与临床病理特征之间的关系。方法:采用荧光定量PCR方法检测81例B细胞非霍奇金淋巴瘤组织和38例淋巴结反应性增生组织(RH)CHFR mRNA的表达水平。结果:①81例B-NHL组织中低水平表达CHFR mRNA,其中2例表达缺失;而在淋巴结反应性增生组中该基因全部表达,差异有统计学意义(P<0.05)。②B-NHL患者中I+II期组和III+IV期组CHFR mRNA表达存在差异,III+IV期表达水平低于I+II期,差异有统计学意义(P<0.05);B-NHL组按IPI评分分0-1分组和2-5分组,高评分组CHFR mRNA表达量低于低评分组,差异具有统计学意义(P<0.05);而CHFR mRNA表达量与年龄、性别、有无症状、LDH水平及ECOG评分无相关性。结论:CHFR表达水平的降低在非霍奇金淋巴瘤的发生过程中具有一定作用,并与其恶性程度及进展相关。
文摘Rituximab has provided a revolutionary contribution to the treatment of B-cell non-Hodgkin’s lymphomas (NHL). A high prevalence of hepatitis C virus (HCV) infection has been described in B-cell NHL patients. Cases of liver dysfunction in HCV-positive patients have been reported with Rituximab-containing regimens. In this paper we review the recent data regarding the effects of Rituximab in NHL patients with HCV infection. We also added a section devoted to improving communication between oncohaematologists and hepatologists. Furthermore, we propose a common methodological ground to study hepatic toxicity emerging during chemotherapy.
